Treatment and prognosis of hepatocellular carcinoma: A population based study in France

Journal of Surgical Oncology

Volumn 98, Issue 7, 2008, Pages 505-509

  Borie, Frédéric ^a,i   Bouvier, Anne Marie ^b   Herrero, Astrid ^a   Faivre, Jean ^b   Launoy, Guy ^c   Delafosse, Patricia ^d   Velten, Michel ^e   Buemi, Antoine ^f   Peng, Jun ^g   Grosclaude, Pascale ^h   Trétarre, Brigitte ^a  

^a Centre de Recherche   (France)

^b Registre Digestif de la Côte d'Or et de la Saône et Loire   (France)

^c Registre Général du Cancer du Calvados Hors Digestif   (France)

^d Registre des Tumeurs de l'Isère   (France)

^e Registre des cancers du Bas Rhin   (France)

^f Registre des Cancers du Haut Rhin   (France)

^g Registre du Cancer de la Somme   (France)

^h Registre des Cancers du Tarn   (France)

ⁱ HÔPITAL SAINT ELOI   (France)

Author keywords

Carcinoma; Hepatocellular; Prognosis; Treatment

Indexed keywords

ALPHA FETOPROTEIN; ANTIANDROGEN; IODINATED POPPYSEED OIL I 131; OCTREOTIDE; RADIOPHARMACEUTICAL AGENT; TAMOXIFEN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BILE DUCT CARCINOMA; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER REGISTRY; CANCER SIZE; CANCER SURVIVAL; CHEMOEMBOLIZATION; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; FRANCE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FUNCTION TEST; LIVER GRAFT; LIVER RESECTION; LIVER SARCOMA; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PALLIATIVE THERAPY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; STATISTICAL SIGNIFICANCE; SURVIVAL RATE; SURVIVAL TIME; SYMPTOM;

AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, HORMONAL; CARCINOMA, HEPATOCELLULAR; EMBOLIZATION, THERAPEUTIC; FEMALE; FRANCE; HEPATECTOMY; HEPATITIS B; HEPATITIS C; HUMANS; IODINE RADIOISOTOPES; IODIZED OIL; LIVER CIRRHOSIS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; MALE; MULTIVARIATE ANALYSIS; NEOPLASM METASTASIS; PALLIATIVE CARE; PROGNOSIS; RADIOIMMUNOTHERAPY; REGISTRIES; TAMOXIFEN;

EID: 56649097560     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.21159     Document Type: Article

References (27)

1. El-Serag HB, Mason AC: Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999;340:745-750.
2. Llovet JM, Brú C, Bruix J: Prognosis of hepatocellular carcinoma: The BCLC staging classification. Semin Liver Dis 1999;19:329-338.
3. Pugh RN, Murray-Lyon IM, Dawson JL, et al.: Transectionof the oesophagus for bleeding oesophageal varices. Br J Surg 1973;60:646-649.
4. Okuda K, Ohtsuki T, Obata H, et al.: Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Cancer 1984;56:918-928.
5. Bruix J, Sherman M: Management of hepatocellular carcinoma. Hepatology 2005;42:1208-1236.
6. Llovet JM, Burroughs A, Bruix J: Hepatocellular carcinoma. Lancet 2003;362:1907-1917.
7. Grazi GL, Ercolani G, Pierangeli F, et al.: Improved results of liver resection for hepatocellular carcinoma on cirrhosis give the procedure added value. Ann Surg 2001;234:71-78.
8. Bismuth H, Chiche L, Adam R, et al.: Surgical treatment of hepatocellular carcinoma in cirrhosis: Liver resection or transplantation? Transplant Proc 1993;25:1066-1067.
9. Mazzaferro V, Regalia E, Doci R, et al.: Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996;334:693-699.
10. Bruix J, Sherman M: Management of hepatocellular carcinoma. Hepatology 2005;42:1208-1236.
11. Sitruk V, Séror O, Grando-Lemaire V, et al.: Traitement percutané du carcinome hépatocellulaire. Gastroenterol Clin Biol 2003;27:381-390.
12. Lencioni RA, Allgaier HP, Cioni D, et al.: Small hepatocellular carcinoma in cirrhosis: Randomized comparison of radiofrequency thermal ablation versus percutaneous ethanol injection. Radiology 2003;228:235-240.
13. Lin SM, Lin CJ, Lin CC, et al.: Radiofrequency ablation improves prognosis compared with ethanol injection for hepatocellular carcinoma ≤4 cm. Gastroenterology 2004;127:1714-1723.
14. Llovet JM, Real MI, Montana X, et al.: Arterial embolization or chemoembolization versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: A randomized controlled trial. Lancet 2002;359:1734-1739.
15. Lo CM, Ngan H, Tso WK, et al.: Randomized controlled trial of transarterial chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002;35:1164-1171.
16. Cammà C, Schepis F, Orlando A, et al.: Transarterial chemoembolization for unresectable hepatocellular carcinoma: Meta-analysis of randomized controlled trials. Radiology 2002;224:47-54.
17. Llovet JM, Bruix J, Barcelona-Clinic-Liver Cancer Group: Systematic review of randomized controlled trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology 2003;37:429-442.
18. Raoul JL, Guyader D, Bretagne JF, et al.: Randomized controlled trial for hepatocellular carcinoma with portal vein thrombosis: Intra-arterial iodine-131-iodized oil versus medical support. J Nucl Med 1994;35:1782-1787.
19. Raoul JL, Guyader D, Bretagne JF, et al.: Prospective randomized trial of chemoembolization versus intra-arterial injection of 131I-labeled-iodized oil in the treatment of hepatocellular carcinoma. Hepatology 1997;26:1156-1161.
20. Yeo W, Mok TS, Zee B, et al.: A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma. J Natl Cancer Inst 2005;97:1532-1538.
21. Burroughs A, Hochhauser D, Meyer T: Systemic treatment and liver transplantation for hepatocellular carcinom: Two ends of the therapeutic spectrum. Lancet Oncol 2004;5:409-418.
22. Barbare JC, Bouché O, Bonnetain F, et al.: Randomized controlled trial of tamoxifen in advanced hepatocellular carcinoma. J Clin Oncol 2005;23:4338-4346.
23. Grimaldi C, Bleiberg H, Gay F, et al.: Evaluation of antiandrogen therapy in unresectable hepatocellular carcinoma: Results of a European Organization for Research and Treatment of Cancer multicentric double-blind trial. J Clin Oncol 1998;16:411-417.
24. Groupe d'Etude et de Traitement du Carcinome Hépatocellulaire: Randomized trial of leuprorelin and flutamide in male patients with hepatocellular carcinoma treated with tamoxifen. Hepatology 2004;40:1361-1369.
25. Llovet JM, Sala M, Castells L, et al.: Randomized controlled trial of interferon treatment for advanced hepatocellular carcinoma. Hepatology 2000;31:54-58.
26. Yuen MF, Poon RT, Lai CL, et al.: A randomized placebo-controlled study of long-acting octreotide for the treatment of advanced hepatocellular carcinoma. Hepatology 2002;36:687-691.
27. Barbare JC, Bouché O, Bonnetain F, et al.: Résultats de l'essai multicentrique randomisé en double-aveugle octréotide- retard versus placebo pour le traitement palliatif du carcinome hépatocellulaire: étude CHOC FFCD-ANGH 2001-01(abstract). Gastroenterol Clin Biol 2005;29:A88.